Insmed (INSM) Projected to Post Earnings on Thursday

Insmed (NASDAQ:INSM - Get Free Report) is anticipated to post its Q4 2024 quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Insmed to post earnings of ($1.17) per share and revenue of $102.31 million for the quarter. Insmed has set its FY 2025 guidance at EPS.Individual that are interested in participating in the company's earnings conference call can do so using this link.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Insmed Trading Down 2.6 %

NASDAQ:INSM traded down $2.17 during midday trading on Friday, reaching $81.44. 1,010,275 shares of the stock traded hands, compared to its average volume of 1,897,493. The company has a fifty day moving average of $74.11 and a 200 day moving average of $73.52. Insmed has a 12 month low of $21.92 and a 12 month high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market capitalization of $14.57 billion, a P/E ratio of -14.69 and a beta of 1.11.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Stifel Nicolaus reduced their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday. Wells Fargo & Company boosted their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Wednesday. Morgan Stanley boosted their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $91.00.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the transaction, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,912,553.60. This represents a 4.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $9,545,887.53. This represents a 13.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 532,207 shares of company stock worth $41,400,465 in the last quarter. Corporate insiders own 4.60% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.